Manhasset, NY – Clifford S. Deutschman, MS, MD, vice chair of research in the Department of Pediatrics at Cohen Children’s Medical Center and an investigator at The Feinstein Institute for Medical Research, presented new definitions and clinical criteria for sepsis and septic shock at the Society of Critical Care Medicine’s (SCCM) 45th Critical Care Congress in Orlando, FL. He was also corresponding author for an article outlining the findings that was published February 23 in The Journal of the American Medical Association (JAMA).
According to the JAMA article, definitions of sepsis were last revised in 2001 and since that time, “considerable advances have since been made” into the pathobiology, management and epidemiology of sepsis, which prompted the need for reexamination. The recommendation, which was developed by Dr. Deutschman and 18 other experts in sepsis pathobiology, clinical trials and epidemiology, notes that sepsis should be, “defined as life-threatening organ dysfunction caused by a dysregulated host response to infection,” and that septic shock should be “defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone.”
Sepsis occurs when molecules released into the bloodstream to fight an injury or infection trigger inflammation throughout the body. Inflammation is necessary for maintaining good health – without inflammation, wounds and infections would never be controlled or heal. However, persistent and constant inflammation often results in organ dysfunction or damage, leading to patient death – 28 to 50 percent of people who suffer from severe sepsis die from the condition.
Dr. Deutschman and the committee provide additional, detailed measurements for identifying sepsis in adults. They recommend using the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more to identify organ dysfunction in a clinical or hospital setting. In out-of-hospital settings, if there is suspicion of infection and a concern sepsis will follow, they recommend using the quickSOFA (qSOFA); at least two of the following clinical criteria: respiratory rate of 22/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia.
Dr. Deutschman has been a sepsis investigator for more than 30 years and has conducted National Institutes of Health-funded, translational studies on molecular and cellular mechanisms in sepsis, with a focus on cell signal transduction pathways and mitochondrial dysfunction. He is a co-author of the recent Choosing Wisely in the ICU, one of a series of recommendations supported by the American Board of Internal Medicine Foundation designed to aid patients with their healthcare decisions. He is the author of more than 100 peer-reviewed papers and the co-editor of the textbook Evidence-Based Practice of Critical Care, the second edition of which was released in 2015.
The new sepsis definitions, and pervasive awareness of the definitions, are critical due to the fact that more American lives are lost due to sepsis than those lost to most cancers, strokes, and heart attacks. And yet, sepsis remains largely unnoticed by patients and healthcare professionals alike, making the condition even deadlier.
A number of Feinstein Institute researchers study sepsis. They study the causes of sepsis and how to create improved treatments. Some researchers develop methods of preventing sepsis occurrence and investigate the mechanisms underlying the cognitive and physical impairment that occurs in up to 25 percent of sepsis survivors. Others study critical proteins implicated in sepsis and their role in organ damage associated with sepsis, including lung and heart injury and anemia caused by severe sepsis. Efforts are also focused on developing novel compounds derived from Chinese herbal therapies to prevent progression of organ damage associated with sepsis.
In addition, researchers in the Feinstein Institute’s Center for Bioelectronic Medicine believe there may be an opportunity to develop therapies for sepsis involving the regulation of vagus nerve activity.
About The Feinstein Institute
The Feinstein Institute for Medical Research, the research arm of Northwell Health, is home to international scientific leaders. We rank in the top 6th percentile of all National Institutes of Health grants awarded to research institutes. We’re making breakthroughs in many areas, including genetics, oncology, brain research, mental health, autoimmunity and immunology, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org.
About Northwell Health
Northwell Health (formerly North Shore-LIJ Health System) is New York State’s largest health care provider and private employer. With 21 hospitals and nearly 450 outpatient practices, we serve more than 1.8 million people annually in the metro New York area and beyond. Our 61,000 employees work to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the School of Graduate Nursing and Physician Assistant Studies. For information on our services in more than 100 medical specialties, visit Northwell.edu.
For media queries, please contact:
Phone: +1 (516) 465-2752